Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapy.

Autor: D'Atri V; School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland., Galy G; Pharmacy, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Buff M; School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland., Imiołek M; Waters Corporation, Geneva 1211, Switzerland., Hübner M; Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland., Undurraga M; Division of Gynecology, Department of Pediatrics and Gynecology, Hôpitaux Universitaires de Genève, Genève, Switzerland., Labidi-Galy SI; Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland; Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland., Guillarme D; School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, Geneva 1211, Switzerland. Electronic address: davy.guillarme@unige.ch., Carrez L; Pharmacy, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Jazyk: angličtina
Zdroj: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Dec 15; Vol. 251, pp. 116410. Date of Electronic Publication: 2024 Aug 15.
DOI: 10.1016/j.jpba.2024.116410
Abstrakt: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new therapeutic approach for patients with peritoneal cancer. So far, most published studies investigated the administration of established cytostatic agents through PIPAC. This study aimed to evaluate the effect of PIPAC on two breakthrough anti-cancer agents, specifically anti-PD1 pembrolizumab, and anti-HER2 antibody-drug conjugate (ADC) - trastuzumab-deruxtecan. We conducted systematic analyses on samples of pembrolizumab and trastuzumab-deruxtecan at clinically relevant concentrations before and after PIPAC administration using an experimental setup of a hermetic container system, mimicking the abdominal cavity and using identical features as in clinical use. We utilized a range of chromatographic and spectroscopic techniques to explore potential alterations in the primary, secondary, and tertiary structures of the drugs, focusing on post-translational modifications resulting from the aerosolization. Our findings indicate that PIPAC did not compromise the integrity of tested biopharmaceuticals. The size variants of both drugs, assessed by size exclusion chromatography (SEC), remained unchanged. Reversed-phase liquid chromatography (RPLC) and hydrophobic interaction chromatography (HIC) revealed no significant differences in hydrophobicity variants, the average drug-to-antibody ratio (DAR), or DAR distribution before and after PIPAC treatment. Circular dichroism (CD) spectroscopy confirmed that the secondary and tertiary structures were preserved. While pembrolizumab showed no change in charge variants post-PIPAC, trastuzumab-deruxtecan exhibited a non-negligible change in the quantity of charge variants on the monoclonal antibody itself, while the payload remained unchanged. This shift could possibly be related to the metallic composition of the CapnoPen® device (made of nickel and chromium) used in PIPAC and for these experiments. Together, our results suggest that PIPAC does not alter the structure of pembrolizumab and trastuzumab-deruxtecan, paving the way for future clinical trials.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. The authors declare the following competing financial interests: Mateusz Imiołek is an employee of Waters (Milford, MA, USA), a manufacturer of chromatography systems and consumables. ACQUITY, UPLC, Empower and BioResolve are trademarks of Waters Technologies Corporation. Capnopen® is a trademark of Capno pharm GmbH. Milli-Q is a trademark of Merck KGaA. Keytruda is a trademark of Merck Sharp & Dohme, LLC. Enhertu is a trademark of Daiichi Sankyo Company Limited. Accutron is a trademark of Medtron AG. AdvanceBio is a trademark of Agilent Technologies Inc. MAbPac is a trademark of Thermo Fisher Scientific AG. Excel is a trademark of Microsoft Corporation. All other trademarks are the property of their respective owners.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: